Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study (scientific article published on 17 March 2015)

Association of circulating fractalkine (CX3CL1) and CX3CR1(+)CD4(+) T cells with common carotid artery intima-media thickness in patients with chronic kidney disease

Q57371429

Fractalkine is an independent predictor of mortality in patients with advanced heart failure

Q58071078

Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects

Q74397732

CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels

Q80371547

Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis

Q80526751

Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris

Q82282569

Expression of the chemokine fractalkine (FKN/CX3CL1) by podocytes in normal and proteinuric rat kidney glomerulus

Q84203212

Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity

Q84353206

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Q26776977

Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease

Q28206251

Of mice and not men: differences between mouse and human immunology

Q28246229

CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival

Q28506756

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

Q29614697

CX3CR1 deficiency does not influence trafficking of adipose tissue macrophages in mice with diet-induced obesity

Q33554073

Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study

Q34043983

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

Q34272627

Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study

Q34289794

The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels

Q34793225

Metabolic syndrome, components, and cardiovascular disease prevalence in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study

Q34985147

Fractalkine is a novel human adipochemokine associated with type 2 diabetes

Q35796996

Fractalkine preferentially mediates arrest and migration of CD16+ monocytes

Q36370923

Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC.

Q36443224

Migratory fate and differentiation of blood monocyte subsets

Q36571680

CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies

Q36623299

Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis

Q36660105

The fractalkine/CX3CR1 system regulates β cell function and insulin secretion

Q37029711

Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.

Q37297615

Fractalkine: a survivor's guide: chemokines as antiapoptotic mediators.

Q37976013

Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway.

Q38131299

The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods

Q40579785

The role of fractalkine in the recruitment of monocytes to the endothelium

Q40887310

Fractalkine expression and the recruitment of CX3CR1+ cells in the prolonged mesangial proliferative glomerulonephritis

Q44004824

Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease.

Q49095210

P433

issue

P304

page(s)

266-273

P577

publication date

2015-03-17

P1433

published in

American Journal of Kidney Diseases

Q4744250

P1476

title

Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study

P478

volume

Reverse relations

cites work (P2860)

Q89179169	Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease
Q26739374	CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection
Q37241472	Common and Rare Genetic Variation in CCR2, CCR5, or CX3CR1 and Risk of Atherosclerotic Coronary Heart Disease and Glucometabolic Traits
Q90732044	Increased fractalkine and vascular dysfunction in obesity and in type 2 diabetes. Effects of oral antidiabetic treatment
Q33611989	Inflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son".
Q99634166	Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study
Q36249768	Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE).